Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback